Status:
RECRUITING
Prospective Assessment of Cost-effectiveness and Side-effects of Depressive Patients Treated With ECT or TCA
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
GGZ inGeest
Canisius-Wilhelmina Hospital
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18+ years
Brief Summary
Prospective observational cohort study to determine cost-effectiveness of ECT compared to medication in the treatment of major depressive disorder (MDD) in the Netherlands.
Detailed Description
Rationale: Currently, detailed information on the cost-effectiveness of ECT based on real-world data is lacking, as well as the comparative cost-effectiveness with respect to medication. Reliable inf...
Eligibility Criteria
Inclusion
- adult patients (\>18 years) with a major depressive disorder who will either start with ECT or medication
- failed response to at least 1 adequate dose-duration trial with antidepressants
- moderate or severe depression (HDRS-17 \>16)
Exclusion
- lifetime diagnosis schizophrenia or schizoaffective disorder, current substance abuse disorder, organic brain syndrome
- the presence of a concurrent significant medical condition impeding the ability to participate
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT05306184
Start Date
January 1 2022
End Date
December 31 2025
Last Update
April 12 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GGz inGeest
Amsterdam, Netherlands
2
RadboudUMC
Nijmegen, Netherlands